Michelle Martinot-Peignoux

Summary

Country: France

Publications

  1. doi request reprint Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA
    Michelle Martinot-Peignoux
    Centre de Recherche Biomedicale Bichat Beaujon CRB3, INSERM U 773, Universite Paris Diderot, 92110 Clichy, France Electronic address
    J Clin Virol 58:401-7. 2013
  2. doi request reprint Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C
    Michelle Martinot-Peignoux
    INSERM, U 773, Centre de Recherche Biomédicale Bichat Beaujon CRB3 and Service d Hépatologie, Hopital Beaujon, AP HP, Universite Paris 7, 92110 Clichy, France
    J Clin Virol 46:216-21. 2009
  3. doi request reprint Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients
    Michelle Martinot-Peignoux
    Centre de Recherche Biomedicale Bichat Beaujon CRB3, INSERM U 773 and Service d Hépatologie Hôpital Beaujon APHP, Universite Paris Diderot, 92110 Clichy, France
    J Hepatol 58:1089-95. 2013
  4. doi request reprint Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin
    Michelle Martinot-Peignoux
    Institut National de la Sante et de la Recherche Medicale, U 773, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Universite Paris VII, Paris, France
    Hepatology 51:1122-6. 2010
  5. doi request reprint HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients
    Michelle Martinot-Peignoux
    INSERM U773 CRB3, Universite Paris Diderot, Paris, France
    Clin Liver Dis 17:399-412. 2013
  6. pmc Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C
    Emilie Estrabaud
    INSERM, UMR1149, Team Physiopathology and Treatment of Viral Hepatitis, Centre de Recherche sur l Inflammation, BP 416, Paris, France
    J Virol 88:6394-402. 2014
  7. doi request reprint Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis
    Ana Carolina Cardoso
    Service d Hepatologie, Hopital Beaujon, AP HP, INSERM U773 CRB3, Universite Denis Diderot Paris7, 100 Boulevard du General Leclerc, 92110 Clichy, France
    J Hepatol 52:652-7. 2010
  8. doi request reprint Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a
    Rami Moucari
    AP HP, Hopital Beaujon, Service d Hepatologie, Clichy, France
    Antivir Ther 14:1183-8. 2009
  9. doi request reprint Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients
    Rami Moucari
    Service d Hepatologie, Hopital Beaujon, Clichy, France
    Hepatology 49:1151-7. 2009
  10. pmc Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody
    Sarah Maylin
    Service de Microbiologie, Hopital Beaujon, Clichy, France
    Liver Int 29:511-7. 2009

Collaborators

Detail Information

Publications36

  1. doi request reprint Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA
    Michelle Martinot-Peignoux
    Centre de Recherche Biomedicale Bichat Beaujon CRB3, INSERM U 773, Universite Paris Diderot, 92110 Clichy, France Electronic address
    J Clin Virol 58:401-7. 2013
    ..We investigated whether serum-based monitoring of hepatitis B surface antigen (HBsAg) and HBV-DNA in asymptomatic HBeAg(-) patients could distinguish these groups...
  2. doi request reprint Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C
    Michelle Martinot-Peignoux
    INSERM, U 773, Centre de Recherche Biomédicale Bichat Beaujon CRB3 and Service d Hépatologie, Hopital Beaujon, AP HP, Universite Paris 7, 92110 Clichy, France
    J Clin Virol 46:216-21. 2009
    ..Early viral monitoring is essential for the management of treatment outcome in patients with chronic hepatitis C. A variety of commercially available assays are now available to quantify HCV-RNA in routine clinical practice...
  3. doi request reprint Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients
    Michelle Martinot-Peignoux
    Centre de Recherche Biomedicale Bichat Beaujon CRB3, INSERM U 773 and Service d Hépatologie Hôpital Beaujon APHP, Universite Paris Diderot, 92110 Clichy, France
    J Hepatol 58:1089-95. 2013
    ..Therefore, we investigated these relationships in a large cohort of unselected, well-characterized, treatment-naïve CHB patients...
  4. doi request reprint Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin
    Michelle Martinot-Peignoux
    Institut National de la Sante et de la Recherche Medicale, U 773, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Universite Paris VII, Paris, France
    Hepatology 51:1122-6. 2010
    ..7%, 95% confidence interval 99.1-100). In relapse patients, serum HCV-RNA levels were 5.623 +/- 0.748, 4.979 +/- 0.870, and 5.216 +/- 0.758 log(10) IU/mL at baseline, W+12, and W+24, respectively...
  5. doi request reprint HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients
    Michelle Martinot-Peignoux
    INSERM U773 CRB3, Universite Paris Diderot, Paris, France
    Clin Liver Dis 17:399-412. 2013
    ..In clinical practice qHBsAg is a simple and reproducible tool that may be used in association with HBV-DNA to classify patients during the natural history of HBV and to monitor therapy. ..
  6. pmc Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C
    Emilie Estrabaud
    INSERM, UMR1149, Team Physiopathology and Treatment of Viral Hepatitis, Centre de Recherche sur l Inflammation, BP 416, Paris, France
    J Virol 88:6394-402. 2014
    ..The association between miR-122 and IFNL3 was stronger than the association between miR-122 and response to treatment. miR-122 may play a role in the early viral decline that is dependent on IFNL3 and the innate immune response...
  7. doi request reprint Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis
    Ana Carolina Cardoso
    Service d Hepatologie, Hopital Beaujon, AP HP, INSERM U773 CRB3, Universite Denis Diderot Paris7, 100 Boulevard du General Leclerc, 92110 Clichy, France
    J Hepatol 52:652-7. 2010
    ..We assessed the influence of combination therapy on the risk of HCC, liver-related complications (ascites, variceal bleeding), and liver-related death (or liver transplantation)...
  8. doi request reprint Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a
    Rami Moucari
    AP HP, Hopital Beaujon, Service d Hepatologie, Clichy, France
    Antivir Ther 14:1183-8. 2009
    ....
  9. doi request reprint Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients
    Rami Moucari
    Service d Hepatologie, Hopital Beaujon, Clichy, France
    Hepatology 49:1151-7. 2009
    ..HBsAg loss was observed in three patients, all with SVR...
  10. pmc Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody
    Sarah Maylin
    Service de Microbiologie, Hopital Beaujon, Clichy, France
    Liver Int 29:511-7. 2009
    ..Viral eradication in chronic hepatitis C patients with sustained virological response (SVR) after interferon (IFN) therapy remains controversial...
  11. doi request reprint Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C
    Sarah Maylin
    Universite Paris VII, Hopital Beaujon, Clichy, France
    Gastroenterology 135:821-9. 2008
    ..It is unclear whether hepatitis C virus (HCV) is eradicated in patients with chronic hepatitis C who achieved a sustained virologic response (SVR)...
  12. ncbi request reprint Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin
    Michelle Martinot-Peignoux
    INSERM, U 773, Centre de Recherche Biomedicale Bichat Beaujon CRB3, Universite Paris VII, Hopital Beaujon, Clichy, France
    Antivir Ther 14:501-11. 2009
    ....
  13. doi request reprint Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir
    Olivier Lada
    Service d Hépatologie and INSERM U773 CRB3, AP HP Hôpital Beaujon, Clichy, France
    Antivir Ther 17:61-70. 2012
    ..The present study was performed to evaluate the quasispecies variability and the in vitro drug susceptibility to approved antiviral drugs of HBV genomes directly isolated from patients' sera...
  14. doi request reprint Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy
    Sarah Maylin
    Service de Microbiologie, Universite Paris VII, Faculté de Médecine Denis Diderot, Hopital Bichat, Paris, France
    J Clin Virol 53:43-7. 2012
    ..Correlation between hepatic HCV-RNA and serum HCV-RNA, severity of liver disease and response to therapy is poorly known...
  15. pmc Impact of ribavirin dose on retreatment of chronic hepatitis C patients
    Christiane Stern
    Service d Hépatologie and INSERM U773 CRB3, Hopital Beaujon, University Paris Diderot, 92110 Clichy, France
    World J Gastroenterol 18:2966-72. 2012
    ..To study the efficacy and factors associated with a sustained virological response (SVR) in chronic hepatitis C (CHC) relapsing patients...
  16. doi request reprint The role of HBsAg quantification for monitoring natural history and treatment outcome
    Michelle Martinot-Peignoux
    INSERM, U 773, CRB3, Universite Paris Diderot, Hopital Beaujon, Clichy, France
    Liver Int 33:125-32. 2013
    ..In clinical practice, HBsAg quantification is a simple and reproducible tool that can be used in association with HBV DNA to classify patients during the natural history of HBV and to monitor therapy...
  17. doi request reprint Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C
    Ana Carolina Cardoso
    Service d Hépatologie and INSERM U773 CRB3, Hopital Beaujon, APHP, University of Paris 7, Clichy, France
    Liver Int 32:612-21. 2012
    ..A secondary analysis was performed to assess whether or not alanine aminotransferase (ALT) levels would impact on the accuracy of TE...
  18. doi request reprint IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C
    Tarik Asselah
    Hepatology Department, AP HP, University Paris Diderot 7 and INSERM U773, CRB3, Beaujon Hospital, Clichy, France
    J Hepatol 56:527-32. 2012
    ..However, there are few data on HCV genotype 4 (HCV-4) infection. We evaluated, in a unique well-characterized cohort of HCV-4 patients, the association of IL28B polymorphism with response to treatment or liver disease severity...
  19. ncbi request reprint Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers
    Michelle Martinot-Peignoux
    Unité de Recherche INSERM U 481, Centre de Recherche Claude Bernard sur les Hépatites Virales and Service d Hépatologie, Hopital Beaujon, 100 Boulevard du General Leclerc, 92110 Clichy, France
    J Hepatol 36:543-6. 2002
    ..The new definition inactive surface antigen (HBsAg) carriers includes an estimated serum HBV DNA level below 105 copies/ml. However, this cut-off value needs to be confirmed...
  20. doi request reprint Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response
    Dan Avi Landau
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Assistance Publique Hopitaux de Paris, Hopital Pitie Salpetriere, Paris, France
    Arthritis Rheum 58:604-11. 2008
    ....
  21. doi request reprint HBsAg quantification: useful for monitoring natural history and treatment outcome
    Michelle Martinot-Peignoux
    INSERM, U 773 Inflammex and Service d Hépatologie, Hôpital Beaujon APHP, Universite Paris Diderot, Clichy, France
    Liver Int 34:97-107. 2014
    ..A level <100 IU/ml during six consecutive months could be a marker of a sustained response after treatment cessation. ..
  22. doi request reprint In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C
    Tarik Asselah
    INSERM U773, Centre de Recherche CRB3, Paris, 75018, France
    J Pathol 221:264-74. 2010
    ..This lack of gene induction may be explained by the inhibiting action of HCV per se (as suggested by in vitro studies) and/or by our finding of the localized nature of hepatocyte ER stress...
  23. doi request reprint Precore/Core promoter variants to predict significant fibrosis in both HBeAg positive and negative chronic hepatitis B
    Martine Lapalus
    Team Physiopathology and Treatment of Viral Hepatitis, Centre de Recherche sur l Inflammation, Laboratory of Excellence Labex INFLAMEX, INSERM, UMR 1149, University Denis Diderot Paris 7, PRES Sorbonne Paris Cité, Paris, France
    Liver Int 35:2082-9. 2015
    ..The objective was to investigate the relationship between fibrosis, host and viral factors to identify non-invasive markers of significant fibrosis in a large cohort of unselected, well-characterized, treatment-naïve CHB patients...
  24. pmc IFI35, mir-99a and HCV genotype to predict sustained virological response to pegylated-interferon plus ribavirin in chronic hepatitis C
    Emilie Estrabaud
    INSERM, UMR1149, Team Viral hepatitis, Centre de Recherche sur l Inflammation, BP 416, Paris, France Université Denis Diderot Paris 7, site Bichat, BP 416, Paris, France Service d Hépatologie, PMAD Hôpital Beaujon, 100 bd du Général Leclerc, Clichy la Garenne, Clichy, France Laboratory of Excellence Labex INFLAMEX, PRES Paris Sorbonne Cité, France
    PLoS ONE 10:e0121395. 2015
    ..876) with a positive predictive value of 86.54% with high sensibility (80%) and specificity (80.4%). This signature may help to characterize patients with low chance to respond to PEG-IFN/ribavirin and to elucidate mechanisms of NR. ..
  25. doi request reprint High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study
    Rami Moucari
    AP HP, Hopital Beaujon, Service d Hepatologie, 100 Boulevard du General Leclerc, 92100 Clichy, France
    J Hepatol 50:1084-92. 2009
    ..To assess the HBsAg seroconversion rate and its impact on the long-term outcome in chronic hepatitis B patients treated with conventional interferon, and to analyze the serum HBsAg concentration prior to seroconversion...
  26. ncbi request reprint Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up
    Corinne Castelnau
    Service d Hepatologie, Hopital Beaujon, AP HP INSERM U773 CRB3, Clichy, and Université Paris 13, Bobigny, France
    Hepatology 44:728-35. 2006
    ..The follow-up of HDV-RNA levels during therapy, which allows the differentiation of various profiles of virological responses, improves treatment monitoring...
  27. doi request reprint Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus
    Sarah Maylin
    Laboratoire de Virologie, Hopital Saint Louis, Paris, France
    J Clin Virol 56:306-11. 2013
    ..No direct comparison has been made between assays that quantify HBeAg...
  28. pmc Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients
    Cédric Laouénan
    INSERM, IAME, UMR 1137, University Paris Diderot, Sorbonne Paris Cité, Paris, France AP HP, Hopital Bichat, Department of Biostatistics, Paris, France
    Antimicrob Agents Chemother 58:5332-41. 2014
    ....
  29. doi request reprint [Hepatitis B: clinical application of HBsAg quantification]
    Michelle Martinot-Peignoux
    Centre de Recherche Biomedicale Bichat Beaujon CRB3, INSERM U 773, Université Paris Diderot Service d hépatologie, Hopital Beaujon, Clichy, France
    Ann Biol Clin (Paris) 71:19-26. 2013
    ..In clinical practice, HBsAg quantification is a simple and reproducible worthwhile tool that can be used in association with HBV DNA to classify patients during HBV infection and to monitor therapy...
  30. doi request reprint Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: a retrospective clinical-pathological study
    Blaise K-Kutala
    Department of Hepatology, Beaujon Hospital, AP HP, Clichy, France INSERM U1137, University Paris 7, UFR of Medicine, France INSERM U1149 CRI, Beaujon Hospital, AP HP, Clichy, France Electronic address
    Dig Liver Dis 47:296-302. 2015
    ..Our objective was to identify the clinical-pathological features of these patients...
  31. pmc Significant gene expression differences in histologically "Normal" liver biopsies: Implications for control tissue
    Tarik Asselah
    Service d Hépatologie and Institut National de la Santé et de la Recherche Médicale INSERM U733, CRB3, Universite Paris Diderot, Assistance Publique Hopitaux de Paris, Hopital Beaujon, Clichy, France
    Hepatology 48:953-62. 2008
    ..In chronic hepatitis C liver samples, a lower or higher expression of a IL8 was found depending on whether the controls were obtained percutaneously or surgically...
  32. pmc Impact of treatment against hepatitis C virus on overall survival of naive patients with advanced liver disease
    Blaise K Kutala
    IAME, UMR 1137, INSERM, Paris, France IAME, UMR 1137, Universite Paris Diderot, Sorbonne Paris Cité, Paris, France AP HP, Hopital Beaujon, Service d Hepatologie, Clichy, France
    Antimicrob Agents Chemother 59:803-10. 2015
    ....
  33. doi request reprint Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G
    Olivier Lada
    Service d Hépatologie and INSERM U773 CRB3, AP HP Hôpital Beaujon, Clichy, France
    Liver Int 32:93-101. 2012
    ..To evaluate the early virological response (EVR) to combined tenofovir-lamivudine or emtricitabine regimen in HBV/HIV-co-infected patients and the long-term efficacy of tenofovir...
  34. doi request reprint Serum Levels of Hepatitis B Surface Antigen Predict Severity of Fibrosis in Patients With E Antigen-Positive Chronic Hepatitis B
    Patrick Marcellin
    Centre de Recherche sur l Inflammation, UMR 1149 Inserm, Universite Paris Diderot, Clichy, France Service d Hépatologie, AP HP Hôpital Beaujon, Clichy, France Electronic address
    Clin Gastroenterol Hepatol 13:1532-9.e1. 2015
    ..We developed a scoring system to determine the degree of fibrosis in patients with genotype B or genotype C hepatitis B virus (HBV) infection and positive for the hepatitis B e antigen...
  35. doi request reprint HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients
    Michelle Martinot-Peignoux
    Centre de Recherche sur l Inflammation CRI, UMR 1149 Inserm, Universite Paris Diderot, Clichy, France
    Liver Int 35:82-90. 2015
    ..Monitoring serum HBsAg levels in chronic hepatitis B (CHB) patients during treatment may provide significant complementary information to HBV DNA measurements. ..
  36. doi request reprint Virological and serological tools to optimize the management of patients with chronic hepatitis B
    Michelle Martinot-Peignoux
    INSERM, UMR1149, Centre de Recherche sur l Inflammation, Paris, France
    Liver Int 36:78-84. 2016
    ..HBsAg levels in serum have been shown to reflect active intrahepatic covalently closed circular DNA (cccDNA) and to have additional value in treatment decisions, especially as an on-treatment marker. ..